Testing a radioactive treatment for advanced stomach and pancreatic cancers

Plain-English translation of NCT07595237 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new radioactive medication called for patients with advanced cancers that have stopped responding to standard treatments. The medication is designed to target cancer cells that have a specific protein on their surface called Claudin 18.2. Researchers want to find the safest and most effective dose of this treatment and see how well it works against these hard-to-treat cancers.

Many patients with advanced stomach, pancreatic, and bile duct cancers run out of standard treatment options. This new radioactive treatment offers a different approach by targeting a specific protein found on these cancer cells, potentially offering hope to patients who haven't benefited from earlier therapies.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced solid tumors (such as gastric, pancreatic, or bile duct cancer) that have progressed despite first-line treatment
your tumor has tested positive for the Claudin 18.2 protein marker
you have a good performance status (able to do light activities or be mostly bedridden)
your blood counts, liver function, and kidney function are within acceptable ranges
you have a life expectancy of at least 6 months

You likely don't qualify if…

you have received other radioactive treatments or similar experimental drugs within the past 4 weeks
you have brain metastases or cancer that has spread to the lining of the brain
you have severe heart disease (New York Heart Association grade III or IV)
you have a very low body mass index (BMI below 18.5) and are malnourished
you are allergic to this medication or similar treatments

What participation looks like

First, you'll have an imaging scan to confirm your tumor has the right protein marker; if it does, you'll receive the radioactive medication in cycles. The trial starts with a lower dose and may increase doses in different groups of patients to find the safest level. You may receive between 1 and 6 treatment cycles, with at least 2 days between your screening scan and your first treatment. You'll have regular follow-up visits and scans to check how your body is responding and monitor for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality